Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,232 Mln
Revenue (TTM)
$405 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.8
Industry P/E
65.05
EV/EBITDA
-57.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.3
Face value
--
Shares outstanding
57,140,500
CFO
$-42.10 Mln
EBITDA
$-439.10 Mln
Net Profit
$-446.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
| -36.9 | 0.1 | -38.3 | -15.1 | 34.8 | 21.6 | -- |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
| 87.7 | 82.0 | -1.7 | -41.0 | 38.2 | -3.0 | 118.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
|
94.6 | 5,232.4 | 404.5 | -123.7 | -26.1 | -17.3 | -- | 6.8 |
| 13.3 | 8,756.4 | 6,685.2 | 715.6 | 16.4 | 12.3 | 12.4 | 1.4 | |
| 250.1 | 6,868.2 | 2,541.1 | -2,228.1 | -110.6 | -31.5 | -- | 1.0 | |
| 248.0 | 6,362.3 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 37.2 | 5,584.0 | 3,446.1 | 79.6 | 6.4 | 4.4 | 70.9 | 3.2 | |
| 71.8 | 8,577.6 | 12,669.0 | 407.0 | 4.0 | 11.8 | 22 | 2.4 | |
| 154.9 | 8,303.7 | 1,973.6 | -494.5 | -15.3 | -41 | -- | 9.3 | |
| 98.6 | 5,733.2 | 1,387.9 | 122.3 | 13.3 | 8.9 | 47.6 | 4.0 | |
| 278.6 | 11,190.6 | 1,240.1 | 42.2 | 4.1 | 3.6 | 270.1 | 9.2 | |
| 124.9 | 7,193.7 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.7 |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent... inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Address: One Glaukos Way, Aliso Viejo, CA, United States, 92656 Read more
Chairman & CEO
Mr. Thomas William Burns
Chairman & CEO
Mr. Thomas William Burns
Headquarters
Aliso Viejo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Glaukos Corp (GKOS) stood at $ 1,035 Mln as on 31-Mar-25
The share price of Glaukos Corp (GKOS) is $94.58 (NYSE) as of 16-May-2025 13:33 EDT. Glaukos Corp (GKOS) has given a return of 34.78% in the last 3 years.
Glaukos Corp (GKOS) has a market capitalisation of $ 5,232 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Glaukos Corp (GKOS) is 6.85 times as on 15-May-2025, a 84% premium to its peers’ median range of 3.72 times.
Since, TTM earnings of Glaukos Corp (GKOS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Glaukos Corp (GKOS) and enter the required number of quantities and click on buy to purchase the shares of Glaukos Corp (GKOS).
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Address: One Glaukos Way, Aliso Viejo, CA, United States, 92656
The CEO & director of Mr. Thomas William Burns. is Glaukos Corp (GKOS), and CFO & Sr. VP is Mr. Thomas William Burns.
There is no promoter pledging in Glaukos Corp (GKOS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,119
|
|
|
876
|
|
|
858
|
|
|
830
|
|
|
719
|
|
|
687
|
|
|
687
|
|
|
573
|
|
|
558
|
| Glaukos Corp (GKOS) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.27
|
|
Operating margin(%)
|
-26.05
|
|
Net Margin(%)
|
-30.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Glaukos Corp (GKOS) was $0 Mln.
$2.96
(
